Wesley Self
-
January 5, 2023
VUMC-led COVID-19 clinical trial platform goes international
The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally. -
December 16, 2022
Bivalent booster vaccine effective in preventing COVID-19 hospitalization in older adults
The new bivalent mRNA COVID-19 booster vaccines that began being used in September are beneficial in preventing COVID-19-associated hospitalization in persons 65 and over. -
December 16, 2022
VUMC Announces VICTR Leadership Transition
-
September 22, 2022
Self named co-principal investigator of Vanderbilt’s Clinical and Translational Science Award
Wesley Self, MD, MPH, a physician-scientist at Vanderbilt University Medical Center, has been named co-principal investigator (co-PI) of Vanderbilt’s Clinical and Translational Science Award (CTSA). -
July 7, 2022
Convalescent plasma doesn’t help severely ill COVID patients: study
A Vanderbilt clinical trial shows that convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover -
April 13, 2022
Additional COVID vaccine helps protect transplant patients
Additional booster doses of vaccine against COVID-19 are particularly important for those who are immunosuppressed, namely those who have had solid organ transplants, a new study shows. -
February 9, 2022
Vanderbilt and CDC research shows third vaccine dose key to preventing omicron hospitalization
Vanderbilt research shows that two doses of an mRNA COVID-19 vaccine result in lower effectiveness for preventing hospitalization for the omicron variant than previous variants. However, importantly, a third (“booster”) vaccine dose significantly improves protection against omicron hospitalization up to 86%.